21 September 2022 - interim results
The AIM-listed supplier of instruments for minimally invasive surgery has announced its interim results for the six months to 30 June which have come in pretty much as expected. Revenues for the period have increased by 28% over 2021 to £5.41m whilst they are also 6% ahead of the pre-pandemic figure of 2019. Clearly, with its products being used in surgery, the fact that many operations have been cancelled during the period of the pandemic has had a negative impact on the company. The welcome recovery in revenues is therefore due to . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
